AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8298199 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 10 mg daily
Number of subjects: 286
Study 8298199 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 20 mg daily
Number of subjects: 286
Study 8298199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 286
Study 8298199 — intervention group
Group type: EXPERIMENTAL
Intervention: CT 100 IU daily
Number of subjects: 286
Study 3080510 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg every day)
Number of subjects: 51
Study 3080510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30074006 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine-calcium carbonate toothpaste (Colgate® Sensitive Pro‐Relief™) with iontophoresis
Number of subjects: 80
Study 30074006 — intervention group
Group type: COMPARATOR
Intervention: 8% arginine-calcium carbonate toothpaste (Colgate® Sensitive Pro‐Relief™) without iontophoresis
Number of subjects: 80
Study 27442155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled nitric oxide (iNO) starting at 5 parts per million, maintenance dose of 2 parts per million for ⩾7 days (n=162)
Number of subjects: 402
Study 27442155 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=240)
Number of subjects: 402
Study 24337471 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded School Mental Health (ESMH) treatment
Number of subjects: 307
Study 24337471 — intervention group
Group type: COMPARATOR
Intervention: Matched high-risk sample (no ESMH services)
Number of subjects: 307
Study 22985572 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 µg·kg(‐1)·min(‐1)
Number of subjects: 164
Study 22985572 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.10 µg·kg(‐1)·min(‐1)
Number of subjects: 164
Study 22985572 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.20 µg·kg(‐1)·min(‐1)
Number of subjects: 164
Study 22985572 — intervention group
Group type: COMPARATOR
Intervention: No drug (Control group D)
Number of subjects: 164
Study 20637962 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana-flavored suspension
Number of subjects: 40
Study 20637962 — intervention group
Group type: COMPARATOR
Intervention: Lemon-flavored single-serving sachet
Number of subjects: 40
Study 18718422 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of reticulated platelets (RPs)
Number of subjects: 90
Study 18718422 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger platelet gate
Number of subjects: 90
Study 15735373 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency SWL (Shockwave Lithotripsy)
Number of subjects: 53
Study 15735373 — intervention group
Group type: COMPARATOR
Intervention: Scheduled SWL (Control)
Number of subjects: 53
Study 12606907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 36
Study 12606907 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 36
Study 10687570 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smoking relapse postpartum
Number of subjects: 228
Study 10687570 — intervention group
Group type: COMPARATOR
Intervention: Abstinence or occasional smoking
Number of subjects: 228
Study 9062044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaja yoga practice for 6 months
Number of subjects: 32
Study 9062044 — intervention group
Group type: COMPARATOR
Intervention: Exercises mimicking Sahaja yoga for 6 months
Number of subjects: 32
Study 9062044 — intervention group
Group type: COMPARATOR
Intervention: Control group (epileptic control)
Number of subjects: 32
Study 1897811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms QD
Number of subjects: 227
Study 1897811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 100 micrograms BID
Number of subjects: 227
Study 1897811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 6291802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.3 mg/day orally for 3 days
Number of subjects: 27
Study 6291802 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone, 0.4 mg intravenously on the third day of clonidine treatment
Number of subjects: 27
Study 6291802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6291802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-induced hypotension and rebound increase in blood pressure after cessation of clonidine
Number of subjects: 27
Study 26365823 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D auxiliary rehabilitation therapy
Number of subjects: 82
Study 28325697 — intervention group
Group type: EXPERIMENTAL
Intervention: sALCAM in diabetic patients with DN
Number of subjects: 107
Study 28325697 — intervention group
Group type: COMPARATOR
Intervention: sALCAM in diabetic patients with normal albuminuria
Number of subjects: 107
Study 28325697 — intervention group
Group type: EXPERIMENTAL
Intervention: ALCAM expression in glomeruli and tubules
Number of subjects: 107
Study 28325697 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ALCAM expression with sclerosis
Number of subjects: 107
Study 28325697 — intervention group
Group type: EXPERIMENTAL
Intervention: S100B expression in glomeruli of diabetic patients
Number of subjects: 107
Study 26179090 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2374697 2 mg
Number of subjects: 22
Study 26179090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24368086 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vaccination with rHVT‐ND vaccine at one day of age
Number of subjects: 0
Study 24368086 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vaccination with rHVT‐ND vaccine
Number of subjects: 0
Study 24368086 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination of rHVT‐ND vaccinated birds with conventional ND vaccines
Number of subjects: 0
Study 24368086 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23866474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 g/kg)
Number of subjects: 62
Study 23866474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19767629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted community-based intervention
Number of subjects: 201
Study 19767629 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study 17513652 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg at induction, placebo at wound closure, parecoxib 40 mg 12 h after induction (pre)
Number of subjects: 62
Study 17513652 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo at induction, parecoxib 40 mg at wound closure, parecoxib 40 mg 12 h after induction (post)
Number of subjects: 62
Study 17513652 — intervention group
Group type: COMPARATOR
Intervention: placebo at induction, at wound closure, and 12 h after induction (control)
Number of subjects: 62
Study 15378186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal amifostine (1,500 mg in a 40-ml enema)
Number of subjects: 67
Study 15378186 — intervention group
Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 67
Study 11744585 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (multi-modal therapy)
Number of subjects: 0
Study 11744585 — intervention group
Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 0
Study 9852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S group) - slowly increased to 5% in 50% nitrous oxide
Number of subjects: 30
Study 9852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (I group) - slowly increased to 3% in 50% nitrous oxide
Number of subjects: 30
Study 9852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P group) - 2.5 mg.kg‐1 with 0.2 microgram.kg‐1 fentanyl
Number of subjects: 30
Study 9852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (I group)
Number of subjects: 30
Study 9852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P group)
Number of subjects: 30
Study 8047560 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises in water
Number of subjects: 20
Study 8047560 — intervention group
Group type: COMPARATOR
Intervention: Exercises on land
Number of subjects: 20
Study 2648650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 55
Study 2648650 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 55
Study 4712484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine with propanidid
Number of subjects: 50
Study 4712484 — intervention group
Group type: COMPARATOR
Intervention: Propanidid, nitrous oxide, and halothane anaesthesia
Number of subjects: 50
Study 30992200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract at 4 mg/mL
Number of subjects: 0
Study 30992200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract at 2 mg/mL
Number of subjects: 0
Study 30992200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (various concentrations)
Number of subjects: 0
Study 30992200 — intervention group
Group type: COMPARATOR
Intervention: Cystone (various concentrations)
Number of subjects: 0
Study 28435494 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS mechanical chest compression device
Number of subjects: 23
Study 28435494 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 23
Study 25307130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185
Study 25307130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185
Study 25307130 — intervention group
Group type: COMPARATOR
Intervention: B50 group
Number of subjects: 1185
Study 25307130 — intervention group
Group type: COMPARATOR
Intervention: Other group
Number of subjects: 1185
Study 25307130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1185
Study 24088003 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency isolation of ostia of pulmonary veins (group 1, n=31)
Number of subjects: 95
Study 24088003 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency modified mini‐maze procedure (group 2, n=30)
Number of subjects: 95
Study 24088003 — intervention group
Group type: COMPARATOR
Intervention: CABG without AF elimination (control group 3, n=34)
Number of subjects: 95
Study 24088003 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal XT devices used in 53 patients (21 in group 1, 25 in group 2, 7 in group 3)
Number of subjects: 95
Study 22018333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 169
Study 22018333 — intervention group
Group type: COMPARATOR
Intervention: Recommended Pharmacological Treatment (RPT)
Number of subjects: 169
Study 22018333 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 169
Study 18804330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 I.U.)
Number of subjects: 26
Study 18804330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16574594 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen specimens stored at 5 degrees C for 24 hours using the Bio-Tranz shipping system
Number of subjects: 128
Study 16574594 — intervention group
Group type: COMPARATOR
Intervention: Semen specimens processed for IUI after 24 hours of storage
Number of subjects: 128
Study 12966613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercise (12 forms of Sun-style tai chi) for 12 weeks
Number of subjects: 72
Study 12966613 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tai chi exercise)
Number of subjects: 72
Study 11153860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast upbeat music
Number of subjects: 27
Study 11153860 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 27
Study 11153860 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐selected music
Number of subjects: 27
Study 11153860 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 27
Study 9190004 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal osteoporosis
Number of subjects: 47
Study 9190004 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls for postmenopausal osteoporosis
Number of subjects: 47
Study 9190004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid-induced osteoporosis
Number of subjects: 47
Study 9190004 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls for glucocorticoid-induced osteoporosis
Number of subjects: 47
Study 1340550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 20
Study 1340550 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous salbutamol (0.5 mg)
Number of subjects: 20
Study 2420347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral local infiltration with 0.25% bupivacaine plain
Number of subjects: 60
Study 31437695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine (standard dose)
Number of subjects: 48
Study 31437695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine (low dose)
Number of subjects: 48
Study 31437695 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48
Study 29794060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) targeting the anterior limb of the internal capsule in nondiabetic patients.
Number of subjects: 14
Study 29794060 — intervention group
Group type: EXPERIMENTAL
Intervention: Optogenetic activation of dopamine D1 receptor-expressing neurons in the nucleus accumbens in mice.
Number of subjects: 14
Study 29794060 — intervention group
Group type: COMPARATOR
Intervention: Systemic dopamine depletion in healthy subjects.
Number of subjects: 14
Study 29794060 — intervention group
Group type: EXPERIMENTAL
Intervention: Case of a diabetes patient treated with DBS.
Number of subjects: 14
Study 27123886 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculotomy combined with cataract surgery
Number of subjects: 142
Study 25348346 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care including treatment as usual plus a psychoeducational intervention (14 sessions)
Number of subjects: 0
Study 25348346 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (pharmacotherapy and regular sessions with psychiatrist)
Number of subjects: 0
Study 25348346 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training of psychotherapists
Number of subjects: 0
Study 22180331 — intervention group
Group type: EXPERIMENTAL
Intervention: High negative pressure suction (HNPS) at -600 mmHg
Number of subjects: 21
Study 22180331 — intervention group
Group type: COMPARATOR
Intervention: Low negative pressure suction (LNPS) at -125 mmHg
Number of subjects: 21
Study 19399700 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10-Symptom-Rating (ISR)
Number of subjects: 1057
Study 17631702 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (10 U hypodermically daily for 10 days)
Number of subjects: 60
Study 17631702 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15853822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal (ID) glucose (300 kcal)
Number of subjects: 12
Study 15853822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric (IG) glucose (300 kcal)
Number of subjects: 12
Study 15853822 — intervention group
Group type: COMPARATOR
Intervention: Intragastric water (control)
Number of subjects: 12
Study 14520844 — intervention group
Group type: EXPERIMENTAL
Intervention: pumpan
Number of subjects: 30
Study 12774460 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 17
Study 12774460 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication
Number of subjects: 17
Study 9125281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% DMM (dimethindene maleate)
Number of subjects: 12
Study 9125281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% azelastine
Number of subjects: 12
Study 9125281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% DMM
Number of subjects: 12
Study 9125281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1995083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright morning light (6:00 to 8:00 AM)
Number of subjects: 19
Study 1995083 — intervention group
Group type: COMPARATOR
Intervention: Bright evening light (7:00 to 9:00 PM)
Number of subjects: 19
Study 1995083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright morning light
Number of subjects: 19
Study 1995083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersomnia
Number of subjects: 19
Study 6638143 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright short‐sitting in an adapted wheelchair
Number of subjects: 26
Study 6638143 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiprone on an inclined prone positioner
Number of subjects: 26
Study 6638143 — intervention group
Group type: COMPARATOR
Intervention: Control variable - level of independent mobility
Number of subjects: 26
Study 30509850 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS plus standard care (n = 67)
Number of subjects: 130
Study 30509850 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (n = 63)
Number of subjects: 130
Study 29316154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (n=71)
Number of subjects: 160
Study 29316154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (n=72)
Number of subjects: 160
Study 29316154 — intervention group
Group type: COMPARATOR
Intervention: Lipid profile and cytokines
Number of subjects: 160
Study 27590259 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas®, BAY 63‐2521) administered over 26 weeks
Number of subjects: 0
Study 27590259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27590259 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas®, BAY 63‐2521)
Number of subjects: 0
Study 25315937 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 36
Study 25315937 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 36
Study 22361121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon® (4 × 10 mL/day)
Number of subjects: 278
Study 22361121 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg/day)
Number of subjects: 278
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon feeding
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon feeding in hospital
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoon feeding at home
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to breast feeding (Trial I)
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to breast feeding (Trial II)
Number of subjects: 144
Study 19710677 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospital stay (Trial II)
Number of subjects: 144
Study 19710677 — intervention group
Group type: COMPARATOR
Intervention: Neonatal morbidity
Number of subjects: 144
Study 17644123 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy for select patients with increasing PSA values below 1.0 ng/ml and lower Gleason score neoplasms.
Number of subjects: 0
Study 17644123 — intervention group
Group type: EXPERIMENTAL
Intervention: Restaging to determine metastatic disease.
Number of subjects: 0
Study 17644123 — intervention group
Group type: EXPERIMENTAL
Intervention: Current knowledge about biochemical relapse management strategies.
Number of subjects: 0
Study 16246659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical levonorgestrel-releasing device (20 microg/day)
Number of subjects: 298
Study 16246659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine levonorgestrel-releasing device (20 microg/day)
Number of subjects: 298
Study 16246659 — intervention group
Group type: COMPARATOR
Intervention: Both groups (cervical and uterine)
Number of subjects: 298
Study 12384633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary gamma radiation
Number of subjects: 0
Study 12384633 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial intravascular ultrasound and angiography
Number of subjects: 0
Study 9428214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 165
Study 9428214 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic controls
Number of subjects: 165
Study 7542675 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (20 mg)
Number of subjects: 0
Study 7542675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2677386 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified relaxation training
Number of subjects: 12
Study 2677386 — intervention group
Group type: COMPARATOR
Intervention: Control group (told stories)
Number of subjects: 12
Study 347569 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate with reduced phenobarbital dose (by about 40%)
Number of subjects: 17
Study 347569 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital alone
Number of subjects: 17
Study 347569 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 17
Study 347569 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate and Phenobarbital
Number of subjects: 17
Study 31916678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken meat consumption
Number of subjects: 0
Study 31916678 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef meat consumption
Number of subjects: 0
Study 31916678 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef consumption
Number of subjects: 0
Study 31916678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken consumption
Number of subjects: 0
Study 31916678 — intervention group
Group type: EXPERIMENTAL
Intervention: General meat intake assessment
Number of subjects: 0